RIPGBM is primarily utilized in the field of medical research, particularly in the study of glioblastoma, an aggressive form of brain cancer. It serves as a targeted therapeutic agent designed to inhibit specific pathways involved in tumor growth and survival. Researchers employ RIPGBM to investigate its efficacy in inducing apoptosis in cancer cells while minimizing damage to healthy tissues. Additionally, it is explored in combination therapies to enhance the overall treatment outcomes for glioblastoma patients. Its application extends to preclinical studies, where it aids in understanding the molecular mechanisms of tumor resistance and identifying potential biomarkers for personalized medicine approaches.